HEALTH

Former Schering-Plough CEO elected to Bausch & Lomb BOD

BY Michael Johnsen

ROCHESTER, N.Y. Former Schering-Plough chairman and CEO Fred Hassan has been elected to the board of Bausch & Lomb, the eyecare company reported Thursday.

“Bausch & Lomb and its customers will benefit from Fred Hassan’s extensive global business experience and his in-depth knowledge of the healthcare industry,” stated Gerald Ostrov, chairman and CEO, Bausch & Lomb. “We will especially value [Hassan’s] insights as we develop and market innovative pharmaceutical products for the global eye health industry.”

Hassan was chairman and CEO of Schering-Plough Corporation from 2003 until its acquisition by Merck earlier this month. Before joining Schering-Plough, he served as chairman and CEO of Pharmacia until that company was acquired by Pfizer in 2003.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

HEALTH

Teva discontinues two-tablet Plan B

BY Michael Johnsen

NORTH WALES, Pa. Teva Women’s Health has discontinued production of the original Plan B emergency contraceptive with the September introduction of its Plan B One-Step, the company recently stated.

“Two-tablet Plan B is not being manufactured or marketed by Teva Women’s Health at this time,” the company stated. “However, some pharmacies and clinics may still have limited quantities of the two-tablet product in-stock.”

Plan B One-Step replaces the two-pill regimen of levonorgestrel tablet, 0.75 mg, taken 12 hours apart with a one-pill, levonorgestrel tablet, 1.5 mg, treatment protocol.

“Emergency contraception is more effective the sooner it’s taken, and Plan B One-Step allows women to act quickly after the unexpected happens because it’s only one pill that’s taken in one dose,” stated Amy Niemann, general manager and SVP of Teva Women’s Health, at the time of the launch.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

HEALTH

Prevacid 24HR to launch with $200 million ad campaign

BY Michael Johnsen

NEW YORK Novartis will storm the antacid market next week with a $200 million ad campaign behind its launch of Prevacid 24HR, the Wall Street Journal reported Wednesday.

Television spots to differentiate Prevacid 24HR from its antacid competition — Procter & Gamble’s Prilosec OTC, McNeil Consumer’s Pepcid Complete, Boehringer Ingelheim’s Zantac 150 and GlaxoSmithKline’s Tums, to name just a few — are expected to begin airing Thursday, underscoring the emotional difficulties of heartburn sufferers.

According to the Journal, the tagline for the antacid new addition will be: “Prevacid 24HR: When you’ve had it with heartburn.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES